Indaptus Therapeutics (NASDAQ:INDP) Releases Earnings Results, Beats Estimates By $1.64 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its earnings results on Friday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64, Zacks reports.

Indaptus Therapeutics Stock Performance

Shares of Indaptus Therapeutics stock opened at $1.59 on Friday. The firm has a fifty day moving average of $2.15 and a two-hundred day moving average of $2.32. The stock has a market capitalization of $3.56 million, a price-to-earnings ratio of -0.07 and a beta of 1.37. Indaptus Therapeutics has a 52 week low of $1.51 and a 52 week high of $19.91.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics has a consensus rating of “Sell”.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.